

(O) JAN 16 2002

I hereby certify that this correspondence is being deposited postage paid First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Jocket No. 50450-8025.US00

U.S. Postal Service with sufficient
missioner for Patents,

Date: December 7, 2001

By: Danessa Gray

#115
1-23-02
N/C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Iversen, et al.

SERIAL No.: 09/493,427

FILED: January 29, 2000

FOR: **ANTISENSE RESTENOSIS
COMPOSITION AND METHOD**

EXAMINER: Epps, J.

ART UNIT: 1635

RECEIVED
JAN 23 2002
TELECENTRE

Amendment and Response to Final Office Action Under 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office action dated August 10, 2001 in the above-identified application, please amend claim 23, and add new claims 26 and 27 as follows:

23. (Twice Amended) In a method aimed at reducing the risk of restenosis in a region of a patient's coronary vessel which has been treated by coronary angioplasty using a catheter with a distal-end expandable balloon, by administering to the vessel region, an antisense compound directed against a target human *c-myc* mRNA sequence, a method for assaying the ability of the antisense compound to reach and interact with *c-myc* mRNA in patient vessel cells, comprising

Do Not Enter
JLE

administering a morpholino antisense compound having a substantially uncharged backbone, and a sequence that spans the start codon of the human *c-myc* gene, to the patient, by placing the compound in contact with, or injecting the compound into, the treated region of the vessel,

at a selected time after said administering, taking a sample of a body fluid from the subject,

detecting in said sample the presence of a nuclease-resistant heteroduplex composed of the antisense compound and the target RNA region, and

correlating the presence of detected heteroduplex in said sample with the ability of said antisense compound to reach and interact with *c-myc* mRNA in vessel cells.

26. (New) The method of claim 23, wherein said administering is selected from a group consisting of: (i) contacting the treated region of said vessel with a reservoir containing said antisense compound and introducing said antisense compound from said reservoir into said vessel by iontophoresis, (ii) injecting said antisense compound directly into the vessel by means of an injection balloon catheter, (iii) contacting the treated region of the vessel with an angioplasty catheter balloon having a surface coating of the antisense compound in diffusible form, (iv) contacting the treated region of the vessel with an intravascular stent having a surface coating of the antisense compound in diffusible form, and, (v) delivering directly into vessel tissue microparticles having said antisense compound in releasable form entrapped therein.

27. (New) The method of claim 23 wherein said administering includes contacting the treated region of the vessel with an intravascular stent having a surface coating of the antisense compound in diffusion form.